CryositeASX:CTE +8.49%51 PB Ratio is 15.54 as of Jun. 25, 2026, which is 4% above its 10-year median of 15.01. GuruFocus rates ASX:CTE with a GF Score™ of 51/100 and a GF Value™ of A$0.94 (Modestly Overvalued). Among 196 Medical Diagnostics & Research companies, Cryosite ranks worse than 92.86% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-25), Cryosite's share price is A$1.15. Cryosite's Book Value per Share for the quarter that ended in Dec. 2025 was A$0.07. Hence, Cryosite's PB Ratio of today is 15.54.
Good Sign:
Cryosite Ltd stock PB Ratio (=14.32) is close to 2-year low of 14.29.
The historical rank and industry rank for Cryosite's PB Ratio or its related term are showing as below:
ASX:CTE'
s PB Ratio Range Over the Past 10 Years
Min: 0.78 Med: 15.01 Max: 86.25
Current: 15.54
During the past 13 years, Cryosite's highest PB Ratio was 86.25. The lowest was 0.78. And the median was 15.01.
ASX:CTE's PB Ratio is ranked worse than 92.86% of 196
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.05
vs ASX:CTE: 15.54
During the past 12 months, Cryosite's average Book Value Per Share Growth Rate was 174.10% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 8.80% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Cryosite was 55.40% per year. The lowest was -42.00% per year. And the median was 3.15% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Cryosite PB Ratio Related Terms
Cryosite PB Ratio Historical Data
* Premium members only.
The historical data trend for Cryosite's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Cryosite's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cryosite PB Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Cryosite's PB Ratio distribution charts can be found below:
* The bar in red indicates where Cryosite's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Cryosite's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Cryosite (ASX:CTE) has a PB Ratio of 15.54 as of Jun. 25, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Cryosite and its competitors. This is near median its historical median of 15.01. Over the past decade, Cryosite's PB Ratio has ranged from 0.78 to 86.25. According to the industry distribution chart, Cryosite ranks #182 out of 196 companies in the Medical Diagnostics & Research industry, placing it in the top 92.9%.
Is Cryosite's PB Ratio too high?
Cryosite's current PB Ratio of 15.54 is near median its 10-year median of 15.01. Over the past 10 years, this metric has ranged from a low of 0.78 to a high of 86.25. The Medical Diagnostics & Research industry median PB Ratio is 2.05. Cryosite's value of 15.54 is 658% above this industry median. Based on the distribution chart, Cryosite ranks #182 out of 196 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Cryosite has a GF Score™ of 51/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cryosite's PB Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Cryosite ranks #182 out of 196 companies for PB Ratio. This places Cryosite in the lower half of its industry. The industry median PB Ratio is 2.05. Cryosite's value of 15.54 is 658% above this benchmark. Historically, Cryosite's own PB Ratio has ranged from 0.78 to 86.25 over the past decade. While the company's 10-year median is 15.01 vs. the industry median of 2.05, Cryosite has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Diagnostics & Research company?
The median PB Ratio among Medical Diagnostics & Research companies is 2.05, based on 196 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cryosite's current PB Ratio of 15.54 is 658% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Cryosite and its competitors. For the Medical Diagnostics & Research industry, the median PB Ratio is 2.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cryosite's current PB Ratio is 15.54, which is near median its own 10-year median of 15.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cryosite stock overvalued right now?
Based on GuruFocus' analysis, Cryosite (ASX:CTE) is currently considered Modestly Overvalued. The stock's GF Value™ is A$0.94, compared to a current price of A$1.15 — trading 22.3% above its estimated fair value. The current PB Ratio is 15.54, which is near median its 10-year median of 15.01 and 658% above the Medical Diagnostics & Research industry median of 2.05. Cryosite's overall GF Score™ is 51/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Cryosite (ASX:CTE), the current PB Ratio is 15.54 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cryosite (ASX:CTE) Overvalued in 2026?
Based on GuruFocus' analysis, Cryosite stock appears to be overvalued.
The current stock price of A$1.15 is trading 22.3% above its estimated GF Value™ of A$0.94.
GuruFocus considers Cryosite to be Modestly Overvalued.
Key valuation signals for ASX:CTE:
PB Ratio: 15.54 (near median its 10-year median of 15.01)
GF Value™: A$0.94 vs. price of A$1.15 (22.3% above fair value)
Industry Position: 658% above the Medical Diagnostics & Research median (#182 of 196)
No single metric tells the full story. See the ASX:CTE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cryosite Ltd provides an integrated clinical trial logistics service, biological storage and sample management service, including the storage of cord blood stem cells for private use. It supports a diverse portfolio of materials, including Good Manufacturing Practice (GMP) clinical trial products, Australian Register of Therapeutic Goods (ARTG) approved medicines, biologics, Research and Development materials, and medical devices, among others. The group's operating segments are: Ambient, cold, and frozen; Ultra-frozen and cryogenic; and Cord blood. The majority of its revenue is generated from the Ambient, cold, and frozen segment, which provides storage and distribution of small-molecule drugs and related products requiring ambient, refrigerated, or frozen conditions.
51GF Score
Get the complete analysis for ASX:CTE
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CTE has been successfully added to your 
